Expeditors International is entering a busy stretch of analyst activity with the stock at $178.22 — up 7.5% on the week and more than 17% above where most of the Street was targeting it just two months ago.
The analyst angle is the real story this week. A wave of target increases landed on July 15, but the consensus remains firmly stuck on Hold. Truist lifted its target from $145 to $175 — a $30 move — while keeping its Hold rating. Stifel nudged its target up to $158 from $154, also holding at Hold. Citizens initiated fresh coverage at Market Perform with no price target attached. The one genuine bull in the room is UBS, which raised its target to $191 on July 9 and kept its Buy — a call that now looks more comfortable given the stock's run. On the other end, Barclays and JP Morgan both sit at Underweight, with targets of $150 and $139 respectively. That means the bear case from two of the bigger names on the Street sits more than $25 below where EXPD is trading today. With eight analysts holding and no upgrades in recent weeks, the consensus is less a vote of confidence than a reluctant acknowledgment that the stock has moved through their models.
Short interest is a secondary story, and not a particularly charged one. Bears have been quietly covering — SI has fallen roughly 7% over the past week and nearly 8% over the past month, landing at 3.4% of the free float. Borrow conditions are completely untroubled: cost to borrow is a negligible 0.44%, and availability is vast at over 2,800% of current short interest, meaning there are around 91 million shares available to lend against fewer than 5 million currently shorted. The ORTEX short score has drifted lower all month, from 39.3 on July 1 to 37.3 today. This is not a squeeze setup, and it is not a high-conviction short thesis either — it is a modestly shorted name where bears have been retreating alongside a rising stock.
Options positioning adds a mild note of caution to an otherwise bullish price picture. The put/call ratio has climbed to 0.57, close to its 52-week high of 0.58 and about one standard deviation above its 20-day average of 0.49. That shift started in late June when the PCR was sitting in the 0.36-0.38 range, and it has moved steadily higher as the stock has rallied. It does not scream fear, but options traders are adding more downside protection than they were a month ago — a natural hedge into a stock that has run hard.
The earnings history adds context worth noting. When EXPD reported Q1 results on May 5, the stock jumped 8.3% the next day and extended the move to 10.5% over the following week. The prior print in February went the other way, a 5.2% drop on the day. The next event is August 4. Given the stock's 7.5% weekly gain and the fresh wave of analyst commentary, the setup heading into that print will be worth watching closely — particularly whether the Hold-heavy Street begins to shift ratings in either direction as EXPD continues to trade well through most published targets.
See the live data behind this article on ORTEX.
Open EXPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
